ES2178352T3 - Derivados de omega-cicloaquil-prostaglandina e1. - Google Patents

Derivados de omega-cicloaquil-prostaglandina e1.

Info

Publication number
ES2178352T3
ES2178352T3 ES99305735T ES99305735T ES2178352T3 ES 2178352 T3 ES2178352 T3 ES 2178352T3 ES 99305735 T ES99305735 T ES 99305735T ES 99305735 T ES99305735 T ES 99305735T ES 2178352 T3 ES2178352 T3 ES 2178352T3
Authority
ES
Spain
Prior art keywords
sub
derivatives
omega
cicloaquil
prostaglandina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99305735T
Other languages
English (en)
Inventor
Shuichi Ohuchida
Kousuke Tani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2178352T3 publication Critical patent/ES2178352T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se presentan derivados de la omega-cicloalquil-prostaglandina E1 de la fórmula (1) en donde R¿sup,1} es OH, etc; X es Cl, F; R{sup,2} es H, alquilo C{sub,1-8}, alquenilo C{sub,2-8}, alquinilo C{sub,2-8} que puede estar sustituido; n es 0-4, las sales no tóxicas de los mismos o los clatratos de ciclodextrina de los mismos pueden unirse fuertemente sobre el receptor de subtipo EP{sub,2}. Por lo tanto, los derivados son útiles para la prevención y/o tratamiento de disfunciones inmunológicas (enfermedades autoinmunes, rechazos de miembros trasplantados, etc), el asma, la formación anormal del hueso, la muerte de las células neuronales, la hepatopatías, los abortos, los nacimientos prematuros o las neuropatías de retina (por ejemplo el glaucoma), etc.
ES99305735T 1998-07-21 1999-07-20 Derivados de omega-cicloaquil-prostaglandina e1. Expired - Lifetime ES2178352T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22105498 1998-07-21

Publications (1)

Publication Number Publication Date
ES2178352T3 true ES2178352T3 (es) 2002-12-16

Family

ID=16760781

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99305735T Expired - Lifetime ES2178352T3 (es) 1998-07-21 1999-07-20 Derivados de omega-cicloaquil-prostaglandina e1.

Country Status (8)

Country Link
US (1) US6235780B1 (es)
EP (1) EP0974580B1 (es)
KR (1) KR100349964B1 (es)
AT (1) ATE218544T1 (es)
DE (1) DE69901658T2 (es)
DK (1) DK0974580T3 (es)
ES (1) ES2178352T3 (es)
PT (1) PT974580E (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
HUE029417T2 (en) 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
JP4662926B2 (ja) * 2003-03-03 2011-03-30 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγ−ラクタム誘導体
EP1654219A2 (en) * 2003-07-18 2006-05-10 Applied Research Systems ARS Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
WO2005009468A1 (ja) 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
EP1806148A4 (en) 2004-10-22 2009-12-02 Ono Pharmaceutical Co THERAPEUTIC PREPARATION FOR INHALATION
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
JP5040650B2 (ja) 2005-06-03 2012-10-03 小野薬品工業株式会社 神経再生および／または保護剤
EP3205644A1 (en) 2005-12-29 2017-08-16 Celtaxsys Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
EP2269611B1 (en) * 2006-11-16 2016-03-23 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
HRP20150882T1 (hr) * 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
WO2018107158A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
CA3045887A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
US10202362B2 (en) 2016-12-09 2019-02-12 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
EP4103192A4 (en) 2020-02-12 2024-02-21 Cytoagents, Inc. Compositions and methods for treating coronavirus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132738A (en) 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
US5204371A (en) 1979-12-10 1993-04-20 Schering Aktiengesellschaft Pharmaceutically active 9-chloroprostaglandins
DE2950027A1 (de) 1979-12-10 1981-06-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
DE3126924A1 (de) 1981-07-03 1983-01-20 Schering Ag, 1000 Berlin Und 4619 Bergkamen 9-fluor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
JPS5883670A (ja) * 1981-11-13 1983-05-19 Teijin Ltd プロスタグランデインｅ↓１類の製造法
WO1994008959A1 (fr) * 1992-10-20 1994-04-28 Taisho Pharmaceutical Co., Ltd. Derive de prostaglandine
JP3502952B2 (ja) * 1992-10-20 2004-03-02 大正製薬株式会社 プロスタグランジン誘導体
DE4330177A1 (de) * 1993-08-31 1995-03-02 Schering Ag Neue 9-Chlor-prostaglandin-derivate
JP3579448B2 (ja) * 1993-12-29 2004-10-20 大正製薬株式会社 プロスタグランジン誘導体、その塩およびその使用
JP3506485B2 (ja) * 1994-04-19 2004-03-15 大正製薬株式会社 プロスタグランジン誘導体
JP3162668B2 (ja) * 1997-02-04 2001-05-08 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
WO1999033794A1 (en) * 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES

Also Published As

Publication number Publication date
EP0974580B1 (en) 2002-06-05
US6235780B1 (en) 2001-05-22
PT974580E (pt) 2002-10-31
DK0974580T3 (da) 2002-09-30
DE69901658T2 (de) 2002-11-21
ATE218544T1 (de) 2002-06-15
KR100349964B1 (ko) 2002-08-22
DE69901658D1 (de) 2002-07-11
EP0974580A1 (en) 2000-01-26
KR20000011866A (ko) 2000-02-25

Similar Documents

Publication Publication Date Title
SHIELDS et al. Complete dislocation of the knee: experience at the Massachusetts General Hospital
ATE260254T1 (de) Omega-cycloalkyl-prostaglandin e2 derivate
EA199900811A1 (ru) Композиция для офтальмологических хирургических операций (варианты) и способ их осуществления
ES2116950T1 (es) Liberacion controlada de farmacos mioticos y midriaticos en la camara anterior.
ATE218544T1 (de) Omega-zykloalkyl-prostaglandin e1 derivate
ES2178808T3 (es) Derivados omega-cicloalquil-prostaglandina e2.
ES2075082T3 (es) Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular.
ES2186670T3 (es) Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular.
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
ES2068955T3 (es) Derivados de 1,2,3,4-tetrahidro-9-acridinamina.
BR9908301A (pt) Derivados de indol e composições farmacêuticas que compreendem os mesmos
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
ES2183148T3 (es) Composiciones oftalmicas que contienen un inhibidor de anhidrasa carbonica y de la goma de xantano.
BRPI0416469A (pt) agente tropicalizante e métodos para fabricação e uso do mesmo
BRPI0215189B8 (pt) composição viscoelástica aquosa, estéril, para uso em procedimentos cirúrgicos oftálmicos
DK0719559T3 (da) Viskøse natriumhyaluronatopløsninger til anvendelse som maskerende væsker i terapeutisk fotokeratektomi under anvendelse af
AR044720A1 (es) Una sulfonamida heterociclica, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, y compuestos utiles como intermediari0s
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
BR0309239A (pt) Derivados de benzopirano substituìdos por aminas secundárias incluindo tetrazol, método para a preparação destes e composições farmacêuticas os contendo
ES2062078T3 (es) Derivados 4-aminofenol y procedimientos para la preparacion de los mismos.
DE69927987D1 (de) Hemmung von mit gewebetrauma verbundenen pathogenen prozessen
BR0011237A (pt) Derivados de benzodioxano, benzofurano ou benzopirano substituìdos com aminoalquila
LEE et al. Macular hole surgery with or without indocyanine green-assisted internal limiting membrane peeling